Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies
- Author:
Eunyoung LEE
1
;
Youngil KOH
;
Junshik HONG
;
Hyeon-Seok EOM
;
Sung-Soo YOON
Author Information
- Publication Type:Review Article
- From:Journal of Korean Medical Science 2021;36(13):e85-
- CountryRepublic of Korea
- Language:English
- Abstract: Acute myeloid leukemia (AML) is a complicated disease characterized by genetic heterogeneity and simultaneous alterations in multiple genes. For decades, its only curative method has been intensive induction chemotherapy with or without allogeneic hematopoietic stem cell transplantation, and this approach cannot be applied to elderly patients, who make up more than 50% of AML patients. Recent advances in genomics facilitated the elucidation of various mutations related to AML, and the most frequent mutations were discovered in epigenetic regulators. Alterations to epigenetic modifications that are essential for normal cell biology, including DNA methylation and histone acetylation, have been identified. As epigenetic dysregulation is an important carcinogenic mechanism and some epigenetic changes are reversible, these epigenetic alterations have become targets for novel drug development against AML. This review summarizes the recent advances in epigenetic therapies for AML and discusses future research directions.
